randomized [resa]
Controlled Study [resa]
effects [qlco]
Raloxifene [orch, phsu]
Sensitivity [qnco]
C-reactive protein [aapp, imft]
Serum lipids NOS [lbpr]
investigate [ftcn]
effects [qlco]
Raloxifene [orch, phsu]
Serum lipids NOS [lbpr]
High sensitivity [lbpr]
C-reactive protein [aapp, imft]
Health [idcn]
postmenopausal [tmco]
Women [popg]
Study [mnob]
Raloxifene [orch, phsu]
Serum lipids NOS [lbpr]
High sensitivity [lbpr]
C-reactive protein [aapp, imft]
Health [idcn]
postmenopausal [tmco]
Women [popg]
participants [popg]
Assigned [ftcn]
mg% [qnco]
Daily [tmco]
Raloxifene [orch, phsu]
Subject [grup]
months [tmco]
Rest [dora]
Subject [grup]
Control Group [grup]
serum cholesterol [lbpr]
Low Density Lipoprotein Cholesterol [bacs, strd]
High Density Lipoprotein Cholesterol [bacs, lipd]
Triglyceride [bacs, lipd]
High sensitivity [lbpr]
C-reactive protein level [lbpr]
Measured [qlco]
baseline [bodm]
Sixth [qnco]
Group [idcn]
Raloxifene [orch, phsu]
treatment [ftcn]
reduction [npop]
serum concentration [qnco]
High sensitivity [lbpr]
C-reactive protein [aapp, imft]
Sixth [qnco]
Compared [acty]
baseline [bodm]
P NOS [aapp, imft]
Sixth [qnco]
Total Cholesterol [lbpr]
Reduced [qlco]
mg% [qnco]
Daily [tmco]
Raloxifene [orch, phsu]
5 6 [fndg]
Compared [acty]
baseline [bodm]
Control Group [grup]
Study [mnob]
Raloxifene [orch, phsu]
Dose [qnco]
mg% [qnco]
Daily [tmco]
serum cholesterol [lbpr]
High sensitivity [lbpr]
C-reactive protein level [lbpr]
Health [idcn]
postmenopausal [tmco]
Women [popg]
Current [tmco]
Study [mnob]
Suggest [idcn]
Raloxifene [orch, phsu]
Favorable [qlco]
Prevention [topp]
Cardiovascular disease [dsyn]
Health [idcn]
postmenopausal [tmco]
Women [popg]
